GlassScriptPhysician profile
Nicholas R Fox
NPI 1467748483
$87,614.96
in general payments reported to CMS, 2019-2025
35 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $342 · 2021: $1,029 · 2022: $1,038 · 2023: $1,671 · 2024: $36K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Consulting Fee: $8,035 · Travel and Lodging: $7,995 · Food and Beverage: $7,276 · Education: $5,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,740.00 |
| Consulting Fee | $8,035.00 |
| Travel and Lodging | $7,994.83 |
| Food and Beverage | $7,276.30 |
| Education | $5,957.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $57,965.49 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $10,473.01 | 2023-2025 | Winrevair |
| United Therapeutics Corporation | $7,740.45 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Intuitive Surgical, INC. | $6,800.73 | 2022-2025 | Da Vinci Surgical System |
| Bayer Healthcare Pharmaceuticals INC. | $732.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $653.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $614.41 | 2019-2025 | Tezspire, Andexxa, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.65 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $315.13 | 2020-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $285.18 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Stryker Corporation | $213.80 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Artix Mt |
| Inari Medical, INC. | $204.80 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $142.73 | 2019-2023 | Yupelri |
| Genzyme Corporation | $138.89 | 2024-2025 | |
| Harmony Biosciences LLC | $105.33 | 2020-2025 | Wakix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Liquidia Technologies, INC. | $102.75 | 2025 | Yutrepia |
| Regeneron Healthcare Solutions, INC. | $93.31 | 2024-2025 | Dupixent |
| Abbvie INC. | $60.96 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.54 | 2023-2025 | Glassia |
| Shionogi INC | $34.85 | 2023-2024 | Fetroja |
| Lilly USA, LLC | $34.31 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $30.52 | 2024 | |
| Baxter Healthcare | $24.86 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $24.43 | 2025 | Ohtuvayre |
| Haemonetics Corporation | $22.44 | 2024 | Teg6s Hemostasis System |
| Resmed Corp | $19.90 | 2024 | |
| Viatris Specialty LLC | $18.91 | 2025 | Yupelri |
| Advanced Respiratory, INC | $18.29 | 2021 | |
| Axsome Therapeutics, INC. | $17.13 | 2025 | Sunosi |
| Boston Scientific Corporation | $15.94 | 2022 | |
| Pfizer INC. | $15.29 | 2024 | |
| Astellas Pharma US INC | $14.97 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2025 | Xifaxan |
| Daiichi Sankyo INC. | $13.66 | 2019 | |
| Inogen, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.